This research project is funded by the Novo Nordisk Foundation.
Lægmandssprog
Duchenne Muscular Dystrophy (DMD) is a progressive, severe, and muscle-wasting disease affecting approximately 1 in 5000 live male births. However, no effective drug is available for curing the disease. Based on highly efficient CRISPR/Cas9 gene editing and stem cell technologies, this project proposes to develop and consolidate a novel therapy to cure DMD (EXOCURE). The EXOCURE is based on ex vivo CRISPR/Cas9repair of DMD mutations in patients’ own skin cells. The D MD-corrected cells will be converted into muscle stem cells by mRNA reprogramming. These DMD-corrected muscle stem cells will be used in the future as an off-the-shelf stem cell product to restore muscle functions in DMD patients. The EXOCURE will create a personalized, safe and effective therapy to cure DMD.